GLP1R and type 2 diabetes mellitus: Currently, two GLP-1 mimetics are approved for the treatment of T2DM, exenatide (Byetta®, Eli Lilly & Co., Indianapolis, IN, US) and liraglutide, while those currently in clinical development include lixisenatide (sanofi-aventis, Paris, France), taspoglutide (Roche, Basel, Switzerland), albiglutide (GlaxoSmithKline, London, UK), LY2189265 (Eli Lilly & Co.)and CJC-1134-PC (ConjuChem, Montreal, Canada) [17,18].